Global Myocardial Infarction (MI) Therapeutics Market 2019-2023 | Evolving Opportunities With AstraZeneca and Bayer AG | Technavio


LONDON–(BUSINESS WIRE)–#Biotechnology–The global myocardial infarction (MI) therapeutics market is poised to grow by USD 1.99 billion during 2019-2023, progressing at a CAGR of almost 5% during the forecast period. Request Free Sample Pages

Read the 127-page research report with TOC on “Myocardial Infarction (MI) Therapeutics Market Analysis Report by Product (Antithrombotics, Vasodilators, Thrombolytics, and Others), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 – 2023”.


The availability of favorable reimbursement schemes and expected approval of stem cell therapies for MI are factors anticipated to boost the growth of the market.

Government agencies and private insurers around the globe are focusing on improving the cardiovascular health of the population by providing favorable reimbursement schemes and policies. Reimbursement programs offer full-time coverage for cardiovascular diseases, including myocardial infarction (MI) and drug therapies. For instance, CMS covers medical services for MI therapeutics through its Medicare program. It also includes Hospital Value-Based Purchasing (VBP) program that provides incentive payments to acute-care hospitals for quality care of Medicare beneficiaries. Thus, the availability of such reimbursement schemes for MI therapeutics is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Myocardial Infarction (MI) Therapeutics Market Companies:


AstraZeneca is headquartered in the UK and operates the business under the Biopharmaceuticals segment. The company offers BRILINTA, CRESTOR, and TENORMIN. CRESTOR and TENORMIN reduce the risk of MI, whereas, BRILINTA reduces the rate of cardiovascular deaths, MI, and stroke.

Bayer AG

Bayer AG is headquartered in Germany and offers products through the following business units: Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. The company offers XARELTO and Aspirin Cardio. XARELTO reduces the risk of stroke and systemic embolism and Aspirin Cardio reduces the risk of MI.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is headquartered in the US and operates under the BioPharmaceuticals business segment. The company offers ELIQUIS, COUMADIN, and PRAVACHOL. ELIQUIS minimizes the risk of stroke and systemic embolism, whereas, COUMADIN minimizes the risk of death, recurrent MI, and thromboembolic events.

Eli Lilly and Company

Eli Lilly and Company is headquartered in the US and offers products through the following business segments: Human pharmaceutical products and Animal health products. The company offers Effient, which is indicated for the reduction of thrombotic cardiovascular events.

Pfizer Inc.

Pfizer Inc. is headquartered in the US and offers products through the following business segments: Innovative Health and Essential Health. The company offers ELIQUIS, which is indicated to minimize the incidence of systemic embolism and stroke in patients with MI.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Myocardial Infarction (MI) Therapeutics Product Outlook (Revenue, USD Million, 2019 – 2023)

  • Antithrombotics
  • Vasodilators
  • Thrombolytics
  • Others

Myocardial Infarction (MI) Therapeutics Regional Outlook (Revenue, USD Million, 2019 – 2023)

  • Asia
  • Europe
  • North America
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Ventricular Assist Devices Market – Global Ventricular Assist Devices Market by geography (Asia, Europe, North America, and ROW) and product (left and right ventricular assist devices and bi-ventricular assist devices).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: https://www.technavio.com

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.